Genmab (GMAB) Citi Annual Global Healthcare Conference 2025 summary

Strategic program updates and clinical pipeline

• Late-stage programs Epkinly, RENA-S, and PETO each hold FDA breakthrough therapy designations, with significant clinical data in 2025 and key registrational readouts expected in 2026, setting up potential launches in 2027.

• The Merus acquisition is aimed at strengthening the oncology antibody platform, with PETO expected to have phase 3 readouts in 2026 and a commercial launch in 2027, targeting over $1 billion in sales by 2029.

• Epkinly is expanding from third-line to earlier lines in DLBCL and follicular lymphoma, with five ongoing phase 3 trials and a $3 billion peak sales target, driven by upcoming front-line DLBCL data in 2026.

• RENA-S has expanded rapidly, with multiple phase 2 and 3 trials in ovarian and endometrial cancers, showing a 50% response rate across all expression levels and aiming for a $2 billion peak sales potential.

• Aclasunamab, in phase 3 for non-small cell lung cancer, is supported by strong survival data and is estimated as a $1 billion opportunity.

Competitive positioning and market strategy

• PETO is positioned as potentially best-in-class and first-in-class in head and neck cancer, with rapid response rates and plans for further expansion, including a new phase 3 in locally advanced disease.

• Epkinly differentiates itself with a single product for both DLBCL and FL, subcutaneous delivery, and strong efficacy and safety, aiming to compete effectively against Roche’s Columvi and Lunsumio.

• RENA-S is considered to have the most advanced and comprehensive data among next-generation ADC folate receptor alpha products, with a focus on broadening indications and leveraging organizational focus.

• Commercialization efforts are heavily resourced, especially in the U.S. and Japan, to support community and academic center uptake as products move into earlier lines of therapy.

Financial performance and capital allocation

• Revenue growth reached 21% and recurring revenue 26% in the first nine months of the year, with a disciplined approach ensuring strong bottom-line results.

• The $5.5 billion Merus acquisition is funded by debt, with a target to reduce gross leverage below three times within 24 months post-close, relying on the strength of the existing business rather than new launches.

• Capital allocation prioritizes reinvestment into late-stage programs and operational efficiency, with ongoing efforts to optimize R&D and commercialization costs.

• M&A remains a future option post-deleveraging, but current focus is on maximizing value from the existing late-stage portfolio and internal innovation.